Adjuvant CDK4/6 Benefits Diverge in Early Breast Cancer
A 2026 meta-analysis found adjuvant abemaciclib and ribociclib improved invasive disease-free survival, while palbociclib did not, reinforcing drug-specific treatment selection.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.